FOXN1 and rectal cancer: To corroborate that finding in vivo, we used a xenograft model, in which human SW1463 rectal cancer cells were transplanted into immunodeficient Foxn1-/-/nude mice, followed by a treatment protocol that closely recapitulates clinical conditions, i.e., fractionated doses of both radiation and chemotherapy (Figure 2B).